LEXG-Lexicon Genetics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics

LXRX 1.250

-12.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (90)	8/23/2001 9:14:42 AM
From: scaram(o)uche	Read Replies (1) of 254

all sorts of useful information in this release........ Thursday August 23, 7:02 am Eastern Time Press Release SOURCE: Lexicon Genetics Incorporated Lexicon Genetics Licenses Patented Gene Targeting Technology To Merck & Co., Inc. THE WOODLANDS, Texas, Aug. 23 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) announced today that it has licensed to Merck & Co., Inc. (NYSE: MRK - news) non-exclusive rights to its gene targeting technologies for use in Merck's internal research programs. Financial terms of the agreement were not disclosed. ``We believe our agreement with Merck is an affirmation of the value of our patented gene targeting technologies,'' said Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Lexicon. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next